172 related articles for article (PubMed ID: 15614819)
1. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations.
Roy S; Jung R; Kerwin BA; Randolph TW; Carpenter JF
J Pharm Sci; 2005 Feb; 94(2):382-96. PubMed ID: 15614819
[TBL] [Abstract][Full Text] [Related]
2. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution.
Zhang Y; Roy S; Jones LS; Krishnan S; Kerwin BA; Chang BS; Manning MC; Randolph TW; Carpenter JF
J Pharm Sci; 2004 Dec; 93(12):3076-89. PubMed ID: 15514986
[TBL] [Abstract][Full Text] [Related]
3. Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist.
Roy S; Katayama D; Dong A; Kerwin BA; Randolph TW; Carpenter JF
Biochemistry; 2006 Mar; 45(12):3898-911. PubMed ID: 16548517
[TBL] [Abstract][Full Text] [Related]
4. Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: glass transition and protein conformation.
Chang BS; Beauvais RM; Dong A; Carpenter JF
Arch Biochem Biophys; 1996 Jul; 331(2):249-58. PubMed ID: 8660705
[TBL] [Abstract][Full Text] [Related]
5. Effect of benzyl alcohol on recombinant human interleukin-1 receptor antagonist structure and hydrogen-deuterium exchange.
Alford JR; Fowler AC; Wuttke DS; Kerwin BA; Latypov RF; Carpenter JF; Randolph TW
J Pharm Sci; 2011 Oct; 100(10):4215-24. PubMed ID: 21557223
[TBL] [Abstract][Full Text] [Related]
6. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor.
Thirumangalathu R; Krishnan S; Brems DN; Randolph TW; Carpenter JF
J Pharm Sci; 2006 Jul; 95(7):1480-97. PubMed ID: 16729274
[TBL] [Abstract][Full Text] [Related]
7. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20.
Webb SD; Cleland JL; Carpenter JF; Randolph TW
J Pharm Sci; 2002 Feb; 91(2):543-58. PubMed ID: 11835212
[TBL] [Abstract][Full Text] [Related]
8. Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist.
Chang BS; Reeder G; Carpenter JF
Pharm Res; 1996 Feb; 13(2):243-9. PubMed ID: 8932444
[TBL] [Abstract][Full Text] [Related]
9. Optimizing storage stability of lyophilized recombinant human interleukin-11 with disaccharide/hydroxyethyl starch mixtures.
Garzon-Rodriguez W; Koval RL; Chongprasert S; Krishnan S; Randolph TW; Warne NW; Carpenter JF
J Pharm Sci; 2004 Mar; 93(3):684-96. PubMed ID: 14762907
[TBL] [Abstract][Full Text] [Related]
10. Particle Formation and Aggregation of a Therapeutic Protein in Nanobubble Suspensions.
Snell JR; Zhou C; Carpenter JF; Randolph TW
J Pharm Sci; 2016 Oct; 105(10):3057-3063. PubMed ID: 27488901
[TBL] [Abstract][Full Text] [Related]
11. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.
Cleland JL; Lam X; Kendrick B; Yang J; Yang TH; Overcashier D; Brooks D; Hsu C; Carpenter JF
J Pharm Sci; 2001 Mar; 90(3):310-21. PubMed ID: 11170024
[TBL] [Abstract][Full Text] [Related]
12. Population balance modeling of aggregation kinetics of recombinant human interleukin-1 receptor antagonist.
Chi EY; Kendrick BS; Carpenter JF; Randolph TW
J Pharm Sci; 2005 Dec; 94(12):2735-48. PubMed ID: 16258998
[TBL] [Abstract][Full Text] [Related]
13. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
[TBL] [Abstract][Full Text] [Related]
14. Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations.
Webb SD; Golledge SL; Cleland JL; Carpenter JF; Randolph TW
J Pharm Sci; 2002 Jun; 91(6):1474-87. PubMed ID: 12115847
[TBL] [Abstract][Full Text] [Related]
15. Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-gamma.
Webb SD; Cleland JL; Carpenter JF; Randolph TW
J Pharm Sci; 2003 Apr; 92(4):715-29. PubMed ID: 12661058
[TBL] [Abstract][Full Text] [Related]
16. Stability of lyophilized human growth hormone.
Salnikova MS; Middaugh CR; Rytting JH
Int J Pharm; 2008 Jun; 358(1-2):108-13. PubMed ID: 18394830
[TBL] [Abstract][Full Text] [Related]
17. Development of a lyophilization formulation that preserves the biological activity of the platelet-inducing cytokine interleukin-11 at low concentrations.
Page C; Dawson P; Woollacott D; Thorpe R; Mire-Sluis A
J Pharm Pharmacol; 2000 Jan; 52(1):19-26. PubMed ID: 10716599
[TBL] [Abstract][Full Text] [Related]
18. Effect of Arginine on the Aggregation of Protein in Freeze-Dried Formulations Containing Sugars and Polyol: II. BSA Reconstitution and Aggregation.
Hackl E; Darkwah J; Smith G; Ermolina I
AAPS PharmSciTech; 2018 Oct; 19(7):2934-2947. PubMed ID: 29980982
[TBL] [Abstract][Full Text] [Related]
19. Development of a lyophilized formulation of interleukin-2.
Hora MS; Rana RK; Wilcox CL; Katre NV; Hirtzer P; Wolfe SN; Thomson JW
Dev Biol Stand; 1992; 74():295-303; discussion 303-6. PubMed ID: 1592178
[TBL] [Abstract][Full Text] [Related]
20. Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models.
Sorret LL; DeWinter MA; Schwartz DK; Randolph TW
Protein Sci; 2018 Jul; 27(7):1191-1204. PubMed ID: 29388282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
